Polymorphisms within the RET proto-oncogene and risk of sporadic medullary thyroid carcinoma.

BACKGROUND Sporadic medullary thyroid carcinoma (sMTC) is an uncommon neoplasia arising from the calcitonin-producing parafollicular cells of the thyroid. Previous studies evaluated whether single nucleotide polymorphisms (SNPs) within RET (a pivotal proto-oncogene for this disease) are associated with the risk for developing sMTC, but the results are inconclusive. METHODS In this work we evaluated the association of RET-SNPs c.74-126G>T (rs2565206), p.Gly691Ser (rs1799939, G>A), p.Leu769= (rs1800861, G>T), p.Ser836= (rs1800862, C>T), and p.Ser904= (rs1800863, C>G) (listed in the order of their chromosomal location) with sMTC. This is one of the largest case-control association studies carried out on sMTC including 585 sMTC cases (negative for germline mutations within RET), 1529 patients affected by sporadic non-medullary thyroid carcinoma (sNMTC), and 989 healthy controls, from central and southern Italy and collected in the period 2000-2017. RESULTS sNMTC patients showed similar genotype and allele frequencies compared to healthy controls. On the other hand, among sMTC patients, the T-allele of p.Leu769= was less frequent (OR=0.70; 95% CI=0.58-0.84; P-value=1.9x10-4) and rare homozygotes TT showed an OR=0.32 (95% CI=0.17-0.60; P-value=2.3x10-4). Moreover, a statistically significant excess of the haplotype 2 (characterized by the alleles T-G-G-C-C of the listed SNPs ) was observed (P-value=3.9x10-3). The SNPs were not associated with the expression of RET mRNA, i.e. they did not work as cis-expression Quantitative Trait Loci (cis-eQTL). However, a strong eQTL-association was found for p.Leu769= and the neighboring gene CSGALNACT2 (P-value=9.3x10-50; effect-size=-0.65), whose function in cancer is unknown. CONCLUSIONS The present study showed that specific RET-haplotypes, in particular haplotype 2 and the T-allele of p.Leu769=, are associated with a reduced risk of sMTC in Italians.

[1]  R. Ciampi,et al.  A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma , 2016, Nature Reviews Endocrinology.

[2]  Douglas B. Evans,et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.

[3]  P. Vitti,et al.  Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer? , 2015, Clinical endocrinology.

[4]  Yuan-qi Zhang,et al.  Quantitative assessment of the association between L769L and S836S polymorphisms at RET gene and medullary thyroid carcinoma risk , 2014, Tumor Biology.

[5]  R. Reis,et al.  The prognostic role of intragenic copy number breakpoints and identification of novel fusion genes in paediatric high grade glioma , 2014, Acta neuropathologica communications.

[6]  I. Ceccherini,et al.  The involvement of the RET variant G691S in medullary thyroid carcinoma enlightened by a meta‐analysis study , 2013, International journal of cancer.

[7]  V. Leite,et al.  High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. , 2011, The Journal of clinical endocrinology and metabolism.

[8]  C. Ugolini,et al.  RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) , 2011, Clinical endocrinology.

[9]  Y. Nikiforov,et al.  Mechanisms of chromosomal rearrangements in solid tumors: The model of papillary thyroid carcinoma , 2010, Molecular and Cellular Endocrinology.

[10]  Torsten Hothorn,et al.  Order‐restricted Scores Test for the Evaluation of Population‐based Case–control Studies when the Genetic Model is Unknown , 2009, Biometrical journal. Biometrische Zeitschrift.

[11]  K. Lorenz,et al.  Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities , 2009, Journal of internal medicine.

[12]  T. Rème,et al.  Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells , 2009, British journal of haematology.

[13]  R. Hofstra,et al.  RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. , 2006, Endocrine reviews.

[14]  Paul Scheet,et al.  A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. , 2006, American journal of human genetics.

[15]  E. Baudin,et al.  Medullary Thyroid Carcinoma , 2016 .

[16]  A. Pinchera,et al.  RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. , 2004, The Journal of clinical endocrinology and metabolism.

[17]  A. Pinchera,et al.  RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. , 2001, The Journal of clinical endocrinology and metabolism.

[18]  J. Milbrandt,et al.  GFRα3 is an orphan member of the GDNF/neurturin/persephin receptor family , 1998 .

[19]  M. Schlumberger,et al.  Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients , 1998 .

[20]  A. Pinchera,et al.  Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene , 1997, Oncogene.

[21]  Lalitha Krishnan,et al.  Somatic mutations in the RET proto‐oncogene in sporadic medullary thyroid carcinoma , 1996, Clinical endocrinology.

[22]  F. Gemignani,et al.  Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. , 2013, Mutation research.